Yesterday it was reported that the CEO of Bio-Techne Corporation (TECH – Research Report), Charles Kummeth, exercised options to buy 7,410 TECH shares at $67.46 a share, for a total transaction value of $499.9K.
Following this transaction Charles Kummeth’s holding in the company was increased by 7.16% to a total of $21.31 million. This is Kummeth’s first transaction since reporting a Buy transaction on SPA back in November 2014
Based on Bio-Techne Corporation’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $192 million and quarterly net profit of $16.46 million. In comparison, last year the company earned revenue of $180 million and had a net profit of $40.86 million. The company has a one-year high of $217.16 and a one-year low of $132.75. TECH’s market cap is $7.28B and the company has a P/E ratio of 78.11.
Starting in February 2019, TECH received 4 Buy ratings in a row.
The insider sentiment on Bio-Techne Corporation has been negative according to 21 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate.